## WHAT IS CLAIMED IS:


- 1. An isolated polynucleotide comprising a polynucleotide having at least 95% identity to a member selected from the group consisting of:
- (a) a polynucleotide encoding a polypeptide comprising amino acid 2 to 92 of SEQ ID NO:2; and
  - (b) the complement of (a).
- 2. The isolated polynucleotide of claim 1 wherein said member is (a).
- 3. The isolated polynucleotide of claim 1 wherein said member is (a) and the polypeptide comprises amino acids 1 to 92 of SEQ/ID NO:2.
- 4. The isolated polynucleotide of claim 1 comprising a polynucleotide encoding a polypeptide comprising the amino acid sequence identical to amino acids 2 to 92 of SEQ ID NO:2.
- 5. The isolated polynucleotide of claim 1, wherein the polynucleotide is DNA.
- 6. The isolated polynucleotide of claim 1 comprising a polynucleotide encoding a polypeptide comprising the amino sequence identical to amino acids 1 to 92 of SEQ ID NO:2.
- 7. The isolated polynucleotide of claim 1, wherein said polynucleotide is RNA.
- 8. A method of making a recombinant vector comprising inserting the isolated polynucleotide of claim 2 into a vector, wherein said polynucleotide is DNA.

- 9. A recombinant vector comprising the polynucleotide of claim 2, wherein said polynucleotide is DNA'.
- 10. A recombinant host cell comprising the polynucleotide of claim 2, wherein said polynucleotide is DNA.
- 11. A method for producing a polypeptide comprising expressing from the recombinant cell of claim 10 the polypeptide encoded by said polynucleotide.
- 12. A process for producing a polypeptide comprising:

  expressing from a recombinant cell

  containing the polynucleotide of claim 4 the polypeptide

  encoded by said polynucleotide.
- 13. A process for producing a polypeptide comprising:
  expressing from a recombinant cell
  containing the polynucleotide of claim 6 the polypeptide
  encoded by said polynucleotide.
- 14. The isolated polynucleotide of claim 1 comprising nucleotides 79 to 351 of SEQ ID NO:1.
- 15. The isolated polymecleotide of claim 1 comprising nucleotides 76 to 351 of SEO ID NO:1.
- 16. The isolated polynucleotide of claim 1 comprising the nucleotides of the sequence of SEQ ID NO:1.
- 17. An isolated polynucleotide comprising a polynucleotide having at least a 95% identity to a member selected from the group consisting of:



- (b) \ the complement of (a).
- 18. The isolated polynucleotide of claim 17, wherein the member is (a).
- 19. The isolated polynucleotide of claim 17, wherein said polynucleotide comprises DNA identical to the coding portion of the human cDNA in ATCC Deposit No. 97304 which encodes a mature polypeptide.
- 20. An isolated polypeptide comprising:

a mature polypeptide having an amino acid sequence encoded by a polynucleotide which is at least 95% identical to the polynucleotide of claim 4.

- 21. The isolated polypeptide of claim 20, comprising amino acids 2 to 92 of sequence of SEQ ID NO:2.
- 22. The isolated polypeptide of claim 20, comprising amino acids 1 to 92 of sequence of SEQ ID NO:2.
- 23. An isolated polypeptide comprising:

  a mature polypeptide encoded by a

  polynucleotide which is at least 95% identical to the human

  cDNA contained in ATCO Deposit No. 97304.
- 24. The isolated polypeptide of claim 23 comprising the mature polypeptide encoded by the human cDNA in ATCC Deposit No. 97304.
- 25. An antibody against the polypeptide of claim 20.



- 26. An antagonist against the polypeptide of claim 20.
- 27. An agonist to the polypeptide of claim 20.
- 28. A method for the treatment of a patient having need of a chemotactic cytokine I comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 20.
- 29. The method of Claim 28 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.
- 30. A method for the treatment of a patient having need to inhibit a chemotactic cytokine I polypeptide comprising: administering to the patient a therapeutically effective amount of the antagonist of Claim 26.
- A method for the treatment of a patient having need of a chemotactic cytokine I polypeptide comprising: administering to the patient a therapeutically effective amount of the agonist of Claim 27.
- 32. A process for diagnosing a disease or a susceptibility to a disease related to expression of the polypeptide of claim 20 comprising:

determining a mutation in the nucleic acid sequence encoding said polypeptide.

A diagnostic process comprising:

analyzing for the presence of the polypeptide of
claim 20 in a sample derived from a host.

ald ai



34. A method for identifying compounds which bind to and activate or inhibit a receptor for the polypeptide of claim 20 comprising:

contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with a compound to be screened under conditions to permit binding to the receptor; and

determining whether the compound binds to and activates or inhibits the receptor by detecting the presence or absence of a signal generated from the interaction of the compound with the receptor.